Publications by authors named "Rana Sullivan"

Claim this Profile
O
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.
Catherine H Marshall, Benjamin A Teply, Jiayun Lu, Lia Oliveira, Hao Wang, Rana Sullivan

JAMA Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations.
Mark C Markowski, Cora N Sternberg, Hao Wang, Tingchang Wang, Laura Linville, Rana Sullivan

Oncologist· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
Mark C Markowski, Hao Wang, Rana Sullivan, Irina Rifkind, Victoria Sinibaldi

Eur Urol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
Eugene Shenderov, Karim Boudadi, Wei Fu, Hao Wang, Rana Sullivan

Prostate· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.
Karim Boudadi, Daniel L Suzman, Valsamo Anagnostou, Wei Fu, Brandon Luber, Rana Sullivan

Oncotarget· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Benjamin A Teply, Hao Wang, Brandon Luber, Rana Sullivan, Irina Rifkind

Lancet Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer.
Benjamin L Maughan, Daniel L Suzman, Brandon Luber, Hao Wang, Stephanie Glavaris, Rana Sullivan

Cancer Chemother Pharmacol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
Lillian L Siu, Roberto Pili, Ignacio Duran, Wells A Messersmith, Eric X Chen, Rana Sullivan

J Clin Oncol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Michael A Carducci, Luna Musib, Merrill S Kies, Roberto Pili, Mylene Truong, Rana Sullivan

J Clin Oncol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Wells A Messersmith, Sharyn D Baker, Lance Lassiter, Rana A Sullivan, Kimberly Dinh

Clin Cancer Res· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis